Risdiplam as an orphan drug treatment of spinal muscular atrophy in adults and children (2 months or older)

References

• Goemans N, Deconinck N. management of neuromuscular diseases in children. Chapter Darras; 2019.
   Google Scholar
• D’Amico A, Mercuri E, Tiziano F, et al. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6(1):71.
   PubMedGoogle Scholar
• Sumner CJ, Paushkin S, Ko CP. Spinal Muscular Atrophy: disease Mechanism and Therapy. Cambridge MA: Academic Press; 2016.
   Google Scholar
• Kaufman P, et al. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol. 2011;68(6):779–786.
   PubMedGoogle Scholar
• Fallini C, Basel GJ, Rossoll W. Spinal muscular atrophy: the role of SMN in axonal mRNA regulation. Brain Res. 2012;1462:81–92.
   PubMed Web of Science ®Google Scholar
• Darras BT. Spinal muscular atrophies. Pediatr Clin North Am. 2015 Jun;62(3):743–766.
   PubMed Web of Science ®Google Scholar
• Calucho M, Bernal S, Alias L, et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord. 2018;28(3):208–2015.
   PubMed Web of Science ®Google Scholar
• Jing Jing Yeo C, Darras BT, D’Amico A. Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease. Pediatr Neurol. 2020 Aug;109:12–19.
   PubMed Web of Science ®Google Scholar
• https://www.fda.gov/media/126109/download ( accessed April 2021).
   Google Scholar
• https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma ( accessed December 2020).
   Google Scholar
• Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713–1722.
   PubMed Web of Science ®Google Scholar
• Biogen Inc. SPINRAZA® (nusinersen) US prescribing information. Dec 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209531lbl.pdf (Apr 2021).
   Google Scholar
• Hua Y, Sahashi K, Hung G, et al. Anitsense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 2010 Jul 12;24(15):1634–1644.
   PubMed Web of Science ®Google Scholar
• Food and drug administration. EVRYSDI™ (risdiplam). South San Francisco CA: Genentech Inc; 2020.
   Google Scholar
• EMA. Evrysdi: summary of positive opinion. 2021. https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-evrysdi_en.pdf (Apr 2021).
   Google Scholar
• European Medicines Agency. Risdiplam. 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/evrysdi
   Google Scholar
• Poirier A, Weetal M, Heinig K, et al. AlsFood and Drug Administration. EVRYSDI™ (risdiplam) South San Francisco CA: Genentech Inc. 2020 nd peripheral organs. Pharmacol Res Perspect. 2018 Nov 29; e447.
   Google Scholar
• Schorling D, Pechmann A, Kirschner J Advances in treatment of SpinEMA. Evrysdi: summary of positive opinion. 2021. https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-evrysdi_en.pdf (Apr 2021).
   Google Scholar
• Naryshkin NA, Weetall M, Dakka A, et al. Motor neuron disease SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science. 2014 Aug 8;345(6197):688–693.
   PubMed Web of Science ®Google Scholar
• Ratni H, Ebeling M, Baird J, et al. Discovery of risdiplam, a selective survival of motor neuron-2. (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018 Aug 9;61(15): 6501–6517.
   PubMed Web of Science ®Google Scholar
• Sturm S, Günther A, Jaber B, et al. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. Br J Clin Pharmacol. 2019 Jan;85(1):181–193.
   PubMed Web of Science ®Google Scholar
• Fowler S, Brink A, Cleary Y, et al. Addressing today’s ADME challenges in the translation of in vitro absorption, distribution, metabolism and excretion characteristics to human: a case study of the SMN2 mRNA splicing modifier risdiplam. Drug Metab Dispos. 2021 October 7;DMD-MR-2021–000563.
   Web of Science ®Google Scholar
• https://www.clinicaltrials.gov/ct2/show/NCT02913482
   Google Scholar
• Baranello G, Darras B, Day J, et al. On behalf of the firefish working group. risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021 Mar 11;384(10):915–923.
   PubMed Web of Science ®Google Scholar
• Darras B, Masson R, Maurkiewicz-Beldzinska M, et al. on behalf of the Firefish working group. Grouprisdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus historical controls. N Engl J Me. 2021 Jul 29;385(5):427–435.
   Google Scholar
• Kolb S, Coffey C, Yankey J, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017 Dec 8;2(6):883–891.
   Google Scholar
• Finkel R, McDermott M, Kaufamnn P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014 Aug 26;83(9):810–817.
   PubMed Web of Science ®Google Scholar
• Masson R, Tanguy-Boespflug O, Darras B, et al. on behalf of the Firefish working group. Group FIREFISH Parts 1 and 2: 24-month safety and efficacy of risdiplam in Type 1 spinal muscular atrophy (SMA) Abstract presented at World Muscle Society (WMS) Congress Sept 2021.
   Google Scholar
• ClinicalTrials.gov. NCT02908685: a study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in Type 2 and 3 spinal muscular atrophy participants (SUNFISH). 2020. https://clinicaltrials.gov/ct2/show/NCT02908685 (Apr 2021).
   Google Scholar
• Trundell D, Le Scouiller S, Le Goff L, et al. Assessment of the validity and reliability of the 32-item motor function measure in individuals with type 2 or non-ambulant Type 3 spinal muscular atrophy. PLoS One. 2020 Sep 18;15(9):e0238786.
   PubMed Web of Science ®Google Scholar
• https://www.clinicaltrials.gov/ct2/show/NCT02908685
   Google Scholar
• Berard C, Payan C, Hodgkinson I, et al. MFM collaborative study group a motor function measure for neuromuscular diseases construction and validation study. Neuromuscul Disord. 2005;15(7):427–435.
   PubMed Web of Science ®Google Scholar
• Mazzone E. Revised upper limb module for SMA. RULM_Generic Manual 10 Nov 2014 ( columbiasma.org)
   Google Scholar
• Main M, Kairon H, Mercuri E, et al. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol. 2003;7(4):155–159.
   PubMed Web of Science ®Google Scholar
• Chabanon A, Seferian A, Daron A, et al. Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study. PLoS One. 2018 Jul 26;13(7):e0201004.
   PubMed Web of Science ®Google Scholar
• Mercuri E, Deconinck N, Mazzone E, et al. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (sunfish part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022 Jan;21(1):42–52.
   PubMed Web of Science ®Google Scholar
• Oskoui M, Day J, Deconinck N, et al. on behalf of the SUNFISH Working Group. SUNFISH Part 2: 24-month efficacy and safety of risdiplam in patients with Type 2/3 SMA. Abstract presented at American Academy of neurology congress (main meeting: 25th April–First May 2021).
   Google Scholar
• Baranello G, Servais L, Bertini E, et al. On behalf of the SUNFISH working group. Pooled safety data from the risdiplam clinical trial development program. Abstract presented at WMS congress. 20- 24th September 2021.
   Google Scholar
• Sergott R, Amorelli G, Baranello G, et al. Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy. Ann Clin Transl Neurol. 2021;8(1):54–65.
   PubMed Web of Science ®Google Scholar
• Veerapandiyan A, Eichinger K, Guntrum D, et al. Nusinersen for older patients with spinal muscular atrophy: a real-world clinical setting experience. Muscle & Nerve. 2020 Feb;61(2):222–226.
   PubMed Web of Science ®Google Scholar
• Servais L, Bertini E, Al-Muhaizea M, et al. RAINBOWFISH: a study of risdiplam (RG7916) in infants with presymptomatic spinal muscular atrophy (SMA).Abstract presented by servais et al at world muscle society (WMS) Congress 2020.
   Google Scholar
• Ramos DM, d’Ydewalle C, Gabbeta V, et al. Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment. J Clin Invest. 2019 Nov 1;129(11):4817–4831.
   Google Scholar